deltatrials
Unknown NCT04993378

Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy

A Clinical Study Initiated by Investigator:Prospectively Predict the Efficacy of Precise Treatment of Gastrointestinal Tumors Based on Peripheral Blood Multi-omics Liquid Biopsy

Sponsor: Shen Lin

Conditions Advanced Gastric Adenocarcinoma Immunotherapy
Interventions EV-array
Updated 4 times since 2021 Last updated: Aug 5, 2021 Started: Nov 1, 2018 Primary completion: Apr 30, 2021 Completion: Jul 30, 2021

A observational or N/A phase clinical study on Advanced Gastric Adenocarcinoma and Immunotherapy, this trial is ongoing. The trial is conducted by Shen Lin and has accumulated 4 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown

    Status: Unknown Status → Unknown

  3. Sep 2023 — Jul 2024 [monthly]

    Unknown Status

    Status: Recruiting → Unknown Status

  4. Sep 2021 — Sep 2023 [monthly]

    Recruiting

    First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shen Lin
Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Beijing, China